Prognostic and diagnostic value of REG4 serum and tissue expression in pancreatic ductal adenocarcinoma

Expression of regenerating islet-derived protein 4 (REG4), a secretory protein involved in cell differentiation and proliferation, is upregulated in inflammatory bowel diseases and in many gastrointestinal malignancies. The prognostic significance of its expression in pancreatic ductal adenocarcinoma is unknown. Our aim was to investigate tumor tissue and serum REG4 expression in pancreatic ductal adenocarcinoma patients. We also evaluated as a control the diagnostic value of serum REG4 level in patients with chronic pancreatitis. Immunohistochemical expression of REG4 was evaluated in 154 surgical specimens and serum REG4 level in 130 samples from pancreatic ductal adenocarcinoma patients treated at Helsinki University Hospital, Finland, in 2000–2011. REG4 tissue and serum expression was assessed in relation to clinicopathological parameters and patient survival. A chronic pancreatitis control group comprised 34 patients who underwent pancreatic resection because of suspicion of malignancy. Significant survival differences were detectable in subgroups: in tumor stages IA–IIA, high serum REG4 level predicted worse survival (p=0.046). In patients with grade I tumor, positive tissue REG4 expression predicted better survival (p=0.006). In multivariate analysis, neither tissue nor serum REG4 expression was independent prognostic factors. Serum REG4 levels were higher in pancreatic ductal adenocarcinoma than in chronic pancreatitis (p=0.002), with diagnostic sensitivity of 45% and specificity of 91%. In logistic regression analysis, a multivariate model with REG4, CA19-9, and age provided sensitivity of 82% and specificity of 79%. REG4 tissue expression is a prognostic marker in subgroups of pancreatic ductal adenocarcinoma patients. Serum REG4 level might be useful in differential diagnosis between pancreatic ductal adenocarcinoma and chronic pancreatitis.

[1]  P. Bachellier,et al.  Prognostic Value of Resection Margin Involvement After Pancreaticoduodenectomy for Ductal Adenocarcinoma: Updates From a French Prospective Multicenter Study , 2017, Annals of surgery.

[2]  A. Juuti,et al.  The Results of Pancreatic Resections and Long-Term Survival for Pancreatic Ductal Adenocarcinoma: A Single-Institution Experience , 2017, Scandinavian journal of surgery : SJS : official organ for the Finnish Surgical Society and the Scandinavian Surgical Society.

[3]  Zu-hua Gao,et al.  Reg proteins promote acinar-to-ductal metaplasia and act as novel diagnostic and prognostic markers in pancreatic ductal adenocarcinoma , 2016, Oncotarget.

[4]  C. Haglund,et al.  Systemic Inflammatory Response and Elevated Tumour Markers Predict Worse Survival in Resectable Pancreatic Ductal Adenocarcinoma , 2016, PloS one.

[5]  K. Alitalo,et al.  PROX1 and β-catenin are prognostic markers in pancreatic ductal adenocarcinoma , 2016, BMC Cancer.

[6]  Zhenggang Zhu,et al.  REG4 promotes peritoneal metastasis of gastric cancer through GPR37 , 2016, Oncotarget.

[7]  J. Mpindi,et al.  REG4 Is Highly Expressed in Mucinous Ovarian Cancer: A Potential Novel Serum Biomarker , 2016, PloS one.

[8]  Harri Mustonen,et al.  REG4 Independently Predicts Better Prognosis in Non-Mucinous Colorectal Cancer , 2014, PloS one.

[9]  H. Tao,et al.  REG4 contributes to the invasiveness of pancreatic cancer by upregulating MMP‐7 and MMP‐9 , 2012, Cancer science.

[10]  Z. Ye,et al.  Evaluation of REG4 for early diagnosis and prognosis of gastric cancer. , 2011, Human pathology.

[11]  Katsuaki Tanaka,et al.  Relationship between RegIV gene expression to outcomes in colorectal cancer , 2011, Journal of surgical oncology.

[12]  R. Andersson,et al.  Systematic review of immunohistochemical biomarkers to identify prognostic subgroups of patients with pancreatic cancer , 2011, The British journal of surgery.

[13]  N. Jamieson,et al.  Tissue Biomarkers for Prognosis in Pancreatic Ductal Adenocarcinoma: A Systematic Review and Meta-analysis , 2011, Clinical Cancer Research.

[14]  Mingyuan Wu,et al.  Reg4 protects against acinar cell necrosis in experimental pancreatitis , 2010, Gut.

[15]  Yusuke Nakamura,et al.  Serum tumor antigen REG4 as a useful diagnostic biomarker in gastric cancer. , 2010, Hepato-gastroenterology.

[16]  M. Miyazaki,et al.  Reg IV expression and clinicopathologic features of gallbladder carcinoma. , 2009, Human pathology.

[17]  J. Dagorn,et al.  The reg4 Gene, Amplified in the Early Stages of Pancreatic Cancer Development, Is a Promising Therapeutic Target , 2009, PloS one.

[18]  Yusuke Nakamura,et al.  Serum REG4 Level Is a Predictive Biomarker for the Response to Preoperative Chemoradiotherapy in Patients With Pancreatic Cancer , 2009, Pancreas.

[19]  S. Natsugoe,et al.  Serum Concentration of Reg IV in Patients with Colorectal Cancer: Overexpression and High Serum Levels of Reg IV Are Associated with Liver Metastasis , 2008, Oncology.

[20]  N. Kamata,et al.  Reg IV is a serum biomarker for gastric cancer patients and predicts response to 5-fluorouracil-based chemotherapy , 2007, Oncogene.

[21]  A. Siriwardena,et al.  Systematic review of carbohydrate antigen (CA 19-9) as a biochemical marker in the diagnosis of pancreatic cancer. , 2007, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[22]  Yusuke Nakamura,et al.  Novel tumor marker REG4 detected in serum of patients with resectable pancreatic cancer and feasibility for antibody therapy targeting REG4 , 2006, Cancer science.

[23]  L. Andersson,et al.  High expression of RELP (Reg IV) in neoplastic goblet cells of appendiceal mucinous cystadenoma and pseudomyxoma peritonei , 2006, Virchows Archiv.

[24]  Y. Takeshima,et al.  Expression and localization of Reg IV in human neoplastic and non‐neoplastic tissues: Reg IV expression is associated with intestinal and neuroendocrine differentiation in gastric adenocarcinoma , 2005, The Journal of pathology.

[25]  Y. Mitani,et al.  Gene Expression Profile of Gastric Carcinoma , 2004, Cancer Research.

[26]  M. Lai,et al.  Overexpression of Reg IV in colorectal adenoma. , 2003, Cancer letters.

[27]  S. Knuutila,et al.  RELP, a novel human REG-like protein with up-regulated expression in inflammatory and metaplastic gastrointestinal mucosa. , 2003, The American journal of pathology.

[28]  T. Lesuffleur,et al.  Reg IV, a new member of the regenerating gene family, is overexpressed in colorectal carcinomas , 2003, International journal of cancer.

[29]  J. Tavernier,et al.  Comparison of leptin- and interleukin-6-regulated expression of the rPAP gene family: evidence for differential co-regulatory signals. , 2002, European cytokine network.

[30]  M. Soares,et al.  Isolation and characterization of a cDNA encoding a novel member of the human regenerating protein family: Reg IV. , 2001, Biochimica et biophysica acta.

[31]  H. Kocher,et al.  Pancreatic Cancer , 2019, Methods in Molecular Biology.

[32]  Deqing Wu,et al.  The pancreatic cancer secreted REG4 promotes macrophage polarization to M2 through EGFR/AKT/CREB pathway. , 2016, Oncology reports.

[33]  A. Jemal,et al.  Cancer statistics, 2016 , 2016, CA: a cancer journal for clinicians.

[34]  Yang Han,et al.  Overexpression of Reg4, alone or combined with MMP-7 overexpression, is predictive of poor prognosis in colorectal cancer. , 2015, Oncology reports.

[35]  Yusuke Nakamura,et al.  Serum tumor antigen REG4 as a diagnostic biomarker in pancreatic ductal adenocarcinoma , 2009, Journal of Gastroenterology.

[36]  M. Fox,et al.  Molecular cloning, genomic organization, and chromosomal localization of the human pancreatitis-associated protein (PAP) gene. , 1994, Genomics.

[37]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.